Quassin Inhibitor

Solid. Powder

98.00%

Store at -20 degree C for 3 years powder
-80 degree C for 2 years in solvent

388.5

<1mg/ml refers to the product slightly soluble or insoluble

C22H28O6

[H][C@]12C[C@@]3([H])[C@H](C)C=C(OC)C(=O)[C@]3(C)[C@@]3([H])C(=O)C(OC)=C(C)[C@]([H])(CC(=O)O1)[C@]23C

76-78-8

Estrogen Receptor/ERR
Antifection
NO Synthase

An HPLC method was employed for purification of the biologically active Quassinoids; Quassin (Q) and neo-Quassin (NQ), further characterized by MALDI-TOF analyses. Purified Q, NQ and the crude bark extract (S1) along with artesunate (AS) were studied for their in vitro anti-plasmodial activity. The in vivo toxicity studies at intraperitoneal doses with higher concentrations of the crude bark extract (S1) in Balb/C mice ruled out the apprehension of toxicity. Interaction studies between the test compounds among themselves (Q+NQ) and individually with artesunate (AS+Q, AS+NQ), were carried out in vitro at four ratios (1:5, 1:2, 2:1 and 5:1) on chloroquine sensitive (MRC-pf-20) and resistant (MRC-pf-303) strains of Plasmodium falciparum. The crude bark extracts of Q. amara exhibited higher P. falciparum inhibitory activity (IC(50)=0.0025microg/ml) as compared to that of the isolated compounds, Quassin (IC(50)=0.06microg/ml, 0.15microM), neo-Quassin (IC(50)=0.04microg/ml, 0.1microM) and also to the positive control, artesunate (IC(50)=0.02microg/ml, 0.05microM)[1]

Others; Microbiology&virology; Immunology/Inflammation